A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: The TARGET study

Pharmacogenomics

Volumn 12, Issue 6, 2011, Pages 815-826

  Newman, William G ^a   Payne, Katherine ^a   Tricker, Karen ^a   Roberts, Stephen A ^a   Fargher, Emily ^a   Pushpakom, Sudeep ^a   Alder, Jane E ^a   Sidgwick, Gary P ^a   Payne, Debbie ^a   Elliott, Rachel A ^b   Heise, Marco ^a   Elles, Robert ^c   Ramsden, Simon C ^c   Andrews, Julie ^a   Houston, J Brian ^a   Qasim, Faeiza ^c   Shaffer, Jon ^c   Griffiths, Christopher E M ^a   Ray, David W ^a   Bruce, Ian ^a   Ollier, William E R ^a   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

azathioprine; pharmacogenetics; randomized controlled trial; thiopurine methyltransferase; TPMT

Indexed keywords

AZATHIOPRINE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; LIVER TOXICITY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MOUTH ULCER; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PANCREATITIS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; SKIN BRUISING; SORE THROAT; TPMT GENE; UNSPECIFIED SIDE EFFECT; WILD TYPE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; DRUG TOXICITY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INFLAMMATION; METHYLTRANSFERASES; NEUTROPENIA; PHENOTYPE;

EID: 79959454066     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.32     Document Type: Article

References (47)

1. Shah J: Criteria influencing the clinical uptake of pharmacogenomic strategies. BMJ 328 (7454), 1482-1486 (2004). (Pubitemid 38829912)
2. Pirmohamed M, Park BK: Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22(6), 298-305 (2001). (Pubitemid 32523913)
3. Fraser AG, Orchard TR, Jewell DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50(4), 485-489 (2002). (Pubitemid 34638866)
4. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W: American Gastroenterological Association: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130(3), 940-987 (2006). (Pubitemid 43374543)
5. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32(5), 651-662 (1980). (Pubitemid 10061685)
6. Lennard L, van Loon JA, Weinshilboum RM: Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46(2), 149-154 (1989). (Pubitemid 19219950)
7. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE: Thiopurine methyltransferase activity in white subjects and black subjects. Clin. Pharmacol. Ther. 55 (1), 15-20 (1994). (Pubitemid 24062187)
8. Yates CR, Krynetski EY, Loennechen T et al.: Molecular diagnosis of thiopurine-S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126(8), 608-616 (1997).
9. Tavadia SM, Mydlarski PR, Reis MD et al.: Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J. Am. Acad. Dermatol. 42(4), 628-632 (2000). (Pubitemid 30479887)
10. Kerstens PJ, Stolk JN, De Abreu RA, Lambooy LH, van de Putte LB, Boerbooms AA: Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum. 38(1), 142-145 (1995).
11. Colombel JF, Ferrari N, Debuysere H et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118(6), 1025-1030 (2000). (Pubitemid 30346978)
12. Schwab M, Schäffeler E, Marx C et al.: Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12(6), 429-436 (2002). (Pubitemid 34918619)
13. Ansari A, Hassan C, Duley J et al.: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16(10), 1743-1750 (2002).
14. Sanderson J, Ansari A, Marinaki T, Duley J: Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann. Clin. Biochem. 41(4), 294-302 (2004). (Pubitemid 38954878)
15. Marshall E: Preventing toxicity with a gene test. Science 302(5645), 588-590 (2003). (Pubitemid 37310902)
16. Black AJ, McLeod HL, Capell H et al.: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129(9), 716-718 (1998). (Pubitemid 28507145)
17. Relling MV, Hancock ML, Rivera GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91(23), 2001-2008 (1999).
18. Seidman EG: Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev. Gastroenterol. Disord. 3(Suppl. 1), 30-38 (2003).
19. Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey AV: Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. QJM 95(7), 439-444 (2002). (Pubitemid 34814662)
20. Carter MJ, Lobo AJ, Travis SP: IBD Section, British Society of Gastroenterology. guidelines for the management of inflammatory bowel disease in adults. Gut 53(S5), V1-V16 (2004). (Pubitemid 39120096)
21. Ford LT, Berg JD: Determination of thiopurine S-methyltransferase activity in erythrocytes using 6-thioguanine as substrate and a non-extraction liquid chromatographic technique. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 798(1), 111-115 (2003). (Pubitemid 37421287)
22. Dervieux T, Boulieu R: Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin. Chem. 44(3), 551-555 (1998). (Pubitemid 28141350)
23. Harvey RF, Bradshaw JM: A simple index of Crohn's-disease activity. Lancet 1(8167), 514 (1980).
24. Dubinsky MC, Lamothe S, Yang HY et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118(4), 705-713 (2000). (Pubitemid 30171620)
25. Escousse A, Mousson C, Santona L et al.: Azathioprine-induced pancytopenia in homozygous thiopurine methyltransferase-deficient renal transplant recipients: a family study. Transplant Proc. 27(2), 1739-1742 (1995).
26. Leipold G, Schütz E, Haas JP, Oellerich M: Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum. 40(10), 1896-1898 (1997). (Pubitemid 27452544)
27. Konstantopoulou M, Belgi A, Griffiths KD, Seale JR, Macfarlane AW: Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase. BMJ 330(7487), 350-351 (2005). (Pubitemid 40239104)
28. Kaskas BA, Louis E, Hindorf U et al.: Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 52(1), 140-142 (2003). (Pubitemid 36020781)
29. Stolk JN, Boerbooms AM, de Abreu RA et al.: Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 41(10), 1858-1866 (1998). (Pubitemid 28465541)
30. Ansari A, Arenas M, Greenfield SM et al.: Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 28(8), 973-983 (2008).
31. Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG: Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am. J. Gastroenterol. 101(12), 2769-2776 (2006). (Pubitemid 44902649)
32. Murphy LA, Atherton D: A retrospective evaluation of AZA in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br. J. Dermatol. 147(2), 308-315 (2002).
33. Higgs J, Payne K, Roberts C, Newman WG: Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? A systematic review and meta-analysis. Pharmacogenomics 11(2), 177-188 (2010).
34. Newman WG, Payne K: Removing barriers to a clinical pharmacogenetics service. PME 5(5), 471-480 (2008).
35. Anstey AV, Wakelin S, Reynolds NJ: British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee: guidelines for prescribing azathioprine in dermatology. Br. J. Dermatol. 151(6), 1123-1132 (2004).
36. Chakravarty K, McDonald H, Pullar T et al.: BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 47(6), 924-925 (2008).
37. Sayani FA, Prosser C, Bailey RJ, Jacobs P, Fedorak RN: Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can. J. Gastroenterol. 19(3), 147-151 (2005). (Pubitemid 40561782)
38. Meggitt SJ, Gray JC, Reynolds NJ: Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 367(9513), 839-846 (2006). (Pubitemid 43363371)
39. Routledge PA, O'Mahony MS, Woodhouse KW: Adverse drug reactions in elderly patients. Br. J. Clin. Pharmacol. 57(2), 121-126 (2004).
40. Ford L, Prout C, Gaffney D, Berg J: Whose TPMT activity is it anyway? Ann. Clin. Biochem. 41(6), 498-500 (2004). (Pubitemid 39574011)
41. Ford L, Kampanis P, Berg J: Thiopurine S-methyltransferase genotype-phenotype concordance: used as a quality assurance tool to help control the phenotype assay. Ann. Clin. Biochem. 46(2), 152-154 (2009).
42. Schaeffeler E, Zanger UM, Eichelbaum M, Asante-Poku S, Shin JG, Schwab M: Highly multiplexed genotyping of thiopurine S-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem. 54(10), 1637-1647 (2008).
43. Ford LT, Berg JD: Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J. Clin. Pathol. 63(4), 288-295 (2010).
44. Payne K, Newman WG, Gurwitz D, Ibaretta D, Phillips KA: TPMT testing in azathioprine: a 'cost-effective use of healthcare resources'? Personalized Med. 6(1), 103-113 (2009).
45. Mallal S, Phillips E, Carosi G et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
46. Mega JL, Close SL, Wiviott SD et al.: Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376(9749), 1312-1319 (2010).
47. Wallentin L, James S, Storey RF et al.: Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749), 1320-1328 (2010).